Residual HIV replication + virus/cell latency + viral sanctuaries

Slides:

Advertisements

Similar presentations

Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA in blood and gut associated.

Advertisements

New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.

Measuring the latent HIV Reservoir

“ The therapeutic effect of FIT- 06, GTU®-Multi-HIVB DNA vaccine, observed in HIV-1 infected people. Results of a Phase II trial”. Prof. Mart Ustav SVP,

Assessment of residual HIV-1 viremia and persistent viral replication in highly suppressed patients: comparison of direct and indirect methods. B. Hernández-Novoa,

The role of HIV infection and Co-infections in Serious Non-AIDS Events Peter W. Hunt, M.D Associate Professor of Medicine, UCSF.

Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.

Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.

1 Using Biostatistics to Evaluate Vaccines and Medical Tests Holly Janes Fred Hutchinson Cancer Research Center.

Measuring the latent HIV Reservoir

Strategies for Targeting and Eradicating the HIV Reservoir

David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.

Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.

Reverse Vaccine in Type 1 DM

HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,

T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.

Estrogen blocks HIV re-emergence from latency and points to gender- specific differences in HIV reservoirs Jonathan Karn International AIDS Society Hammer.

Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.

Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.

Rémi Cheynier Victor Appay Anne Hosmalin Gianfranco Pancino Vincent Vieillard Brigitte Autran Françoise Brun-Vezinet Charlotte Charpentier Diane Descamps.

Projeto Praça Onze Universidade Federal do Rio de Janeiro Clinical Trials at AIDS Vaccine ‘09 Scientific Journalists Training Program Global HIV Vaccine.

1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens Giron, LB; Tenore, S; Gabriel, R; Janini,

HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to.

Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir IAS HIV RESERVOIRS WORKSHOP, 16 & 17 JULY 2010, VIENNA.

Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.

11 NAPWA Symposium 6 th IAS Meeting An HIV-based Lentiviral Vector Vaccine Achieves Functional Cure Post-challenge in a Subset of Vaccinated Macaques Dr.

Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.

Title Box. “Towards an HIV Cure”: Presentation Outline -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART.

HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.

Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:

Immune reconstitution Anjie Zhen, PhD

Date of download: 5/28/2016 From: Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases Ann.

Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

#AIDS2016 Dolutegravir (DTG) plus Rilpivirine (RPV) in Suppressed Heavily Pretreated HIV-Infected Patients A. Díaz, J.L. Casado, F.

Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,

Treatment-Naïve Adults

Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP

RALTEGRAVIR vs LPV/R FOR LATE-PRESENTERS PREGNANT WOMEN.

Virological and immunological efficacy of regimen including MVC

coinciding with biphasic immune reconstitution

Switch from TDF-based to Elvitegravir-Cobicistat-TAF-FTC Study 109

Katsin MA, Vitebsk State Medical University (Belarus)

Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY

Switch to Etravirine from Efavirenz due to CNS Toxicity SSAT-029 STUDY

Feedback meeting September 2017

HEATHER Feedback Meeting

Intensification with INSTI

LPV-RTV versus LPV-RTV + ZDV-3TC in Treatment-Naïve MONARK Trial

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Baseline tumor biopsies

Human Immunodeficiency Virus Type 1 Protease Inhibitor Modulates Activation of Peripheral Blood CD4+ T Cells and Decreases Their Susceptibility to Apoptosis.

Jeffrey F. Scott, Lopa M. Das, Sayeeda Ahsanuddin, Yuqi Qiu, Amy M

Evaluation of tolerability, pharmacokinetics, and anti-retroviral activity of MK-8591 in treatment-naïve HIV-1-infected adult subjects MK-8591 (EFdA)

Y. Sun, J. Li, J. Ma, C. Wang, F. Bai, K. Zhao, Z. Yu, W. Kang,

Phase 3 Treatment Naïve HIV Coinfection

Reverse Transcriptase

Volume 5, Issue 6, Pages (June 2002)

Quasispecies tropism and compartmentalization in gut and peripheral blood during early and chronic phases of HIV-1 infection: possible correlation with.

Li Huang Duke University, North Carolina, USA

Treatment of keloid scars with intralesional triamcinolone and 5-fluorouracil injections – a randomized controlled trial KE Hietanen, TA Järvinen, H.

Switch to LPV/r monotherapy

Switch to DRV/r monotherapy

Comparison of NRTI combinations

Volume 158, Issue 5, Pages (August 2014)

Intensification with INSTI

Switch to ATV/r monotherapy

NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN

Presentation transcript:

Residual HIV replication + virus/cell latency + viral sanctuaries Auranofin plus Nicotinamide impact HIV reservoir among ART suppressed HIV individuals (WEPDB0105) Ricardo Sobhie Diaz; Federal University of Sao Paulo, Brazil Residual HIV replication + virus/cell latency + viral sanctuaries Pilot, proof of concept open label randomized clinical trial (NCT02961829) 30 patients allocated in 6 groups

Results: Proviral HIV DNA over time % of CD4+ T cells CD38+, and CD8+ T cells and CD38+ in G6 Cell activation markers: white bars = baseline; green bars = week 20. Proviral HIV DNA over time Levels of proviral DNA quantitation at PBMCs in G5 and G6.

Interventions were safe with no major AE Results (ctd): Interventions were safe with no major AE transient decreases in CD4 counts at weeks 8 and 12 in auranofin groups. Decrease in Ab quantitation over time in G1-5. None of the patients negativated Proviral HIV DNA at rectal biopsies. Correlation between of HIV proviral DNA quantitation at PBMCs and at rectal tissues at baseline but not at the end of study. Conclusions/Discussion: Auranofin and nicotinamide (NA) significantly decrease viral DNA in intensified ART-treated individuals, with one individual evolving with undetectable levels of HIV proviral DNA in PBMCs. There was a decrease in the micro-inflammation levels in the auranofin and NA and ART intensification group (G6) as suggested by the activation markers in the CD4+ and CD8+ T cells. After Autologous Dendritic cell vaccination one individual from G6 also evolved to undetectable levels of HIV proviral DNA in PBMCs. Auranofin and nicotinamide administration in combination with intensified ART was well tolerated and safe.